Open access
Open access
Powered by Google Translator Translator

Chest Medicine

CDC Report: Unvaccinated 5 times more likely to get COVID-19 and 29 times more likely to be hospitalized than vaccinated individuals.

25 Aug, 2021 | 09:56h | UTC

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: CDC: Unvaccinated 5 times more likely to get COVID-19 – CIDRAP

 

Commentary on Twitter

 

What we actually know about the vaccines and the delta variant – “Covid-19 vaccines still are effective in preventing hospitalization. But vaccinated people are more likely to get sick than before”.

25 Aug, 2021 | 09:09h | UTC

What we actually know about the vaccines and the delta variant – Vox

 

CDC Report: Vaccine effectiveness dropped from 91% to 66% since the SARS-CoV-2 Delta variant became predominant.

25 Aug, 2021 | 09:11h | UTC

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

Vaccines are less protective against Delta infection but still reduce risk by two-thirds, US CDC study shows – CNN

Messenger RNA COVID vaccines 66% effective against Delta: US study – Associated Press

 

Perspective | Delta has changed the pandemic risk calculus – “If you’re confused about what you can do right now, you should be”.

25 Aug, 2021 | 09:05h | UTC

Delta Has Changed the Pandemic Risk Calculus – The Atlantic

 

Third Pfizer dose 86% effective in over 60s, Israeli HMO says.

25 Aug, 2021 | 09:01h | UTC

Third Pfizer dose 86% effective in over 60s, Israeli HMO says – Reuters

 

Commentary on Twitter

 

Perspective | That ‘damn machine’: the dark side of mechanical ventilators in the ICU.

25 Aug, 2021 | 09:04h | UTC

That ‘damn machine’: the dark side of mechanical ventilators in the ICU – STAT

 

Covid-19 booster vaccines: What we know and who’s doing what.

24 Aug, 2021 | 10:04h | UTC

Covid-19 booster vaccines: What we know and who’s doing what – The BMJ

 

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

24 Aug, 2021 | 10:06h | UTC

RCT: Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19 – Together Clinical Trials

Related:

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 

How will Delta evolve? Here’s what the theory tells us.

24 Aug, 2021 | 09:58h | UTC

How will Delta evolve? Here’s what the theory tells us – The Conversation

 

Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.

24 Aug, 2021 | 10:01h | UTC

The FDA Really Did Have to Take This Long – The Atlantic

 

How I Do It: Considering lung transplantation for patients with COVID-19.

24 Aug, 2021 | 09:55h | UTC

How I Do It: Considering lung transplantation for patients with COVID-19 – CHEST

 

Related:

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Report: Lung transplantation for 3 patients with severe COVID-19

 

COVID vaccines protect against Delta, but their effectiveness wanes.

24 Aug, 2021 | 09:57h | UTC

COVID vaccines protect against Delta, but their effectiveness wanes – Nature

Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

 

M-A: Patient–ventilator asynchrony, impact on clinical outcomes and effectiveness of interventions.

24 Aug, 2021 | 08:51h | UTC

Patient–ventilator asynchrony, impact on clinical outcomes and effectiveness of interventions: a systematic review and meta-analysis – Journal of Intensive Care

 

Among patients receiving mRNA vaccines, clinically significant symptoms were more frequent following dose 2, following dose 1 in patients with previous SARS-CoV-2 infection, and in those who received the Moderna vaccine.

22 Aug, 2021 | 23:54h | UTC

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers – JAMA Internal Medicine

 

Commentary on Twitter

 

[Preprint] Study shows symptomatic breakthrough infections are probably less transmissible than SARS-CoV-2 infections in unvaccinated individuals.

22 Aug, 2021 | 23:59h | UTC

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.

23 Aug, 2021 | 00:03h | UTC

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Invited commentary: Awake prone positioning in COVID-19: is tummy time ready for prime time?

Related:

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

 

Commentary on Twitter

 

Evidence mounts that people with breakthrough infections can spread Delta easily.

22 Aug, 2021 | 23:57h | UTC

Evidence mounts that people with breakthrough infections can spread Delta easily – National Geographic

Original study: Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent – Wisconsin, July 2021 – medRxiv

 

Commentary on Twitter

 

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

22 Aug, 2021 | 23:51h | UTC

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Invited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Related:

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

 

Commentary on Twitter

 

Study Commentaries: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial.

22 Aug, 2021 | 23:52h | UTC

Commentary 1: JC: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial – St Emlyn’s

Commentary 2: An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – The Bottom Line

Original study: [Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

 

NICE Guideline: Obstructive sleep apnea/hypopnea syndrome and obesity hypoventilation syndrome in over 16s.

22 Aug, 2021 | 23:10h | UTC

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s – National Institute for Health and Care Excellence

 

Study: Macrolide use significantly associated with both prevalent and incident tinnitus.

22 Aug, 2021 | 22:11h | UTC

Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss – Journal of Antimicrobial Chemotherapy

Commentary: Macrolide Use and Tinnitus: A New Safety Ringtone? – NEJM Journal Watch (free for a limited period)

 

[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

20 Aug, 2021 | 10:03h | UTC

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – University of Oxford

Commentaries:

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds – Forbes

Expert reaction to preprint looking at the impact of the delta variant on vaccine effectiveness – Science Media Centre

Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard

 

Commentary on Twitter

 

Covid-19: How many variants are there, and what do we know about them?

20 Aug, 2021 | 10:00h | UTC

Covid-19: How many variants are there, and what do we know about them? – The BMJ

 

Commentary on Twitter

 

New SARS-CoV-2 variants have changed the pandemic. What will the virus do next?

20 Aug, 2021 | 09:58h | UTC

New SARS-CoV-2 variants have changed the pandemic. What will the virus do next? – Science

 

Commentary on Twitter

 

A grim warning from Israel: Vaccination blunts, but does not defeat Delta.

20 Aug, 2021 | 09:56h | UTC

A grim warning from Israel: Vaccination blunts, but does not defeat Delta – Science

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.